Associated Papers
Tramadol-related fatalities: Metabolic ratios & SNPs/INDELs belonging to UGT1A8, UGT2B7, ABCC2, and SLC22A1.
Aly SM et al.
Forensic Science International. Genetics, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Tagawa K et al.
Toxicology Mechanisms and Methods, 2023
Genetic Factors in Familial Manifestation of Primary Mediastinal Large B-Cell Lymphoma over Two Generations.
Juskevicius D et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2023
Racial Disparity in Drug Disposition in the Digestive Tract.
Gao S et al.
International Journal of Molecular Sciences, 2021
Worsening of Kidney Transplant Function During 2-Year Follow-up Is Associated With the Genetic Variants of CYP3A4, MDR1, and UGT1A9.
Hryniewiecka E et al.
Transplantation Proceedings, 2020
UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
In Vitro Study on Influences of UGT1A8 Gene Polymorphisms on Mycophenolate Mofetil Metabolism.
Zhou Z et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation, 2018
Prevalence of UDP-glucuronosyltransferase polymorphisms (UGT1A6∗2, 1A7∗12, 1A8∗3, 1A9∗3, 2B7∗2, and 2B15∗2) in a Saudi population.
Alkharfy KM et al.
Saudi Pharmaceutical Journal : Spj : the Official Publication of the Saudi Pharmaceutical Society, 2017
Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.
Hu DG et al.
Drug Metabolism Reviews, 2016
Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms.
Pithukpakorn M et al.
Pharmacogenomics and Personalized Medicine, 2014
Polymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancer.
Wang M et al.
Plos One, 2013
UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.
Fukuda T et al.
Therapeutic Drug Monitoring, 2012
High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk.
Dura P et al.
International Journal of Oncology, 2012
Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
Wong NS et al.
Pharmacogenetics and Genomics, 2011
Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients.
Zhao W et al.
Journal of Clinical Pharmacology, 2010
Phenotype prediction of nonsynonymous single nucleotide polymorphisms in human phase II drug/xenobiotic metabolizing enzymes: perspectives on molecular evolution.
Hao D et al.
Science China. Life Sciences, 2010
Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment.
Ginsberg G et al.
Critical Reviews in Toxicology, 2010
Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele.
Woillard JB et al.
British Journal of Clinical Pharmacology, 2010
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
Ramírez J et al.
Future Oncology (london, England), 2010
UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
van Schaik RH et al.
Clinical Pharmacology and Therapeutics, 2009
UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.
Prausa SE et al.
Clinical Pharmacology and Therapeutics, 2009
Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.
Balliet RM et al.
Cancer Research, 2009
Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population.
Ménard V et al.
Human Mutation, 2009
Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.
Johnson LA et al.
European Journal of Clinical Pharmacology, 2008
Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
Zhang WX et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2008
[Review on gene polymorphisms of UDP-glucuronosyltransferases and genetic susceptibility of cancer].
Wang Y et al.
Wei Sheng Yan Jiu = Journal of Hygiene Research, 2008
Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9).
Takahashi H et al.
Basic & Clinical Pharmacology & Toxicology, 2008
Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A).
Strassburg CP et al.
Critical Reviews in Clinical Laboratory Sciences, 2008
The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Lévesque E et al.
Clinical Pharmacology and Therapeutics, 2007
Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid.
Bernard O et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2006
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.
Thibaudeau J et al.
Cancer Research, 2006
Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk.
van der Logt EM et al.
Carcinogenesis, 2004
Functional polymorphisms of UDP-glucuronosyltransferases 1A1, 1A6 and 1A8 are not involved in chronic pancreatitis.
Verlaan M et al.
Pharmacogenetics, 2004
Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation.
Burchell B
American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice, 2003
Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3.
Huang YH et al.
Pharmacogenetics, 2002